Skip to main content
Fig. 30 | Cancer Nanotechnology

Fig. 30

From: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Fig. 30

Expression of specific proteins COX-II, NFκB, and TNF-α was quantified at the end of the protocol in the PC group compared to pure VC and NFs of VC-loaded TCs-HA treatment groups (n = 10, mean ± SD, p ≤ 0.05, ***highly significant)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us